Effector T Cell Reprogramming With HDACi and IL-21 for Persistence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing adoptive T cell therapy (ACT) methods face challenges in generating central memory T cells with self-renewal capabilities from well-differentiated effector cells, limiting their persistence and therapeutic efficacy.
Innovation Solution
A method involving the use of histone deacetylase inhibitors (HDACi) and interleukin-21 (IL-21) to reprogram effector T cells into central memory T cells, enhancing their persistence and proliferative ability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If well-differentiated effector T cells are used for adoptive cell therapy, then immediate cytotoxic activity is achieved, but proliferative ability and persistence in vivo are limited
Solution Approach 1:
The patent changes the differentiation state parameter of T cells by treating effector T cells with HDAC inhibitors and IL-21, transforming them from a well-differentiated state with limited proliferation to a central memory phenotype with enhanced proliferative ability and persistence
Solution Approach 2:
Instead of attempting to improve the function of well-differentiated effector T cells directly, the patent inverts the approach by de-differentiating them into central memory T cells, which inherently possess both the desired persistence and proliferative capacity
2Duration of action of moving object
If central memory T cells are generated from effector T cells, then self-renewal capability and persistence are improved, but the differentiation process requires additional culturing steps
Solution Approach 1:
The patent combines multiple functions into a single culturing step: effector T cell depletion, central memory T cell generation, and enrichment all occur simultaneously during the HDAC inhibitor and IL-21 treatment period, eliminating the need for separate differentiation and selection steps
3Quantity of substance
If HDAC inhibitors and IL-21 are used for reprogramming, then central memory T cell enrichment is achieved, but additional reagents and culturing conditions are required
Solution Approach 1:
The patent employs the body's own biological mechanisms by using endogenous pathways responsive to HDAC inhibitors and IL-21 to drive the reprogramming of T cells, leveraging natural epigenetic and cytokine-mediated differentiation processes rather than introducing external genetic or complex chemical systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The reprogramming process enriches for central memory T cells, improving their persistence and proliferative capacity, making them more effective for adoptive cell therapy.
Implementation Method 1
culturing the starting population of lymphocytes comprising T EFF cells or the sample enriched in T EFF cells in the presence of a histone deacetylase inhibitor (HDACi)
Data Source
Figure 1A~1B
Figure 1C
Figure 2A
AI summary
The present disclosure provides methods for re-programming effector T cells to a central memory phenotype comprising culturing the effector T cells with a histone deacetylase inhibitor (HDACi) and IL-21. Further provided are methods of treating cancer comprising administering the central memory T cells.